RIAS
MAZE

Rachor Investment Advisory Services’s Maze Therapeutics MAZE Stock Holding History

Rachor Investment Advisory Services’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$90 – 451
2026
Q1 		$90 Sell
3
-3
-50% -$132 ﹤0.01% 456
2025
Q4 		$249 Buy
+6
New +$206 ﹤0.01% 385

Other funds holding MAZE

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AC
AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Rachor Investment Advisory Services's MAZE Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 3 shares — an estimated $90 sold.

Rachor Investment Advisory Services first reported a position in MAZE in Q4 2025 and held it in 2 quarters. The position peaked at $249 in Q4 2025. 28 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 3 Maze Therapeutics shares in Q2 2026, an estimated $90.
  • Rachor Investment Advisory Services first reported a position in Maze Therapeutics in Q4 2025 and held it in 2 quarters.
  • Rachor Investment Advisory Services's Maze Therapeutics position peaked at $249 in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.